A series of outstanding achievements have been made in the construction of the molecular imaging clinical translation platform of Peking University Cancer Hospital

In the diagnosis and treatment of major diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, and neurodegenerative diseases, molecular imaging technology has irreplaceable advantages

The team of Yang Zhi and Zhu Hua from the Department of Nuclear Medicine of Peking University Cancer Hospital took advantage of the unique clinical advantages of Peking University Medicine to routinely realize the production and clinical/scientific use of the new next-generation solid target nuclides 64Cu, 124I, and 89Zr

1.

Figure 1: Multi-modal imaging design of PMNs-II-813 nanoprobe for integrated diagnosis and treatment

2.

Figure 2: Schematic diagram of the mechanism of action and clinical transformation of the ACE2 targeting probe

3.

Figure 3: Al18F-FAPI applied to Micro PET/CT and clinical PET/CT in tumor-bearing mice

4.

Figure 4: PET clinical conversion of I-124 labeled PD1 monoclonal antibody

5.

Figure 5: PET analysis of 68Ga-LMW in tumors with different PD-L1 expression levels

Actively responding to the "Mid-Long Term Development Plan for Medical Isotope (2021-2035)" issued by the state, the molecular imaging clinical transformation platform of the Nuclear Medicine Department of Peking University Cancer Hospital has actively promoted domestic production with a series of strong medical isotope drug research and development capabilities and excellent clinical transformation.

Attachment: References (? stands for common first, * stands for communication)

1.

2.

3.

4.

5.